Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for GeoVax Labs Inc. (GOVX : NSDQ)
 
 • Company Description   
GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.

Number of Employees: 17

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.67 Daily Weekly Monthly
20 Day Moving Average: 3,172,933 shares
Shares Outstanding: 15.93 (millions)
Market Capitalization: $10.62 (millions)
Beta: 3.36
52 Week High: $11.18
52 Week Low: $0.43
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -41.50% -43.69%
12 Week -19.60% -32.38%
Year To Date -73.00% -74.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1900 LAKE PARK DRIVE SUITE 380
-
SMYRNA,GA 30080
USA
ph: 678-384-7220
fax: 678-384-7281
investor@geovax.com http://www.geovax.com
 
 • General Corporate Information   
Officers
David A. Dodd - Chief Executive Officer;President
Mark W. Reynolds - Chief Financial Officer
Randal D. Chase - Director
Dean G. Kollintzas - Director
Nicole Lemerond - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 373678606
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 15.93
Most Recent Split Date: 1.00 (0.07:1)
Beta: 3.36
Market Capitalization: $10.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.50 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.17
Price/Cash Flow: -
Price / Sales: 1.90
EPS Growth
vs. Year Ago Period: 81.78%
vs. Previous Quarter: -50.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 89.47%
ROE
06/30/25 - -
03/31/25 - -511.96
12/31/24 - -884.81
ROA
06/30/25 - -
03/31/25 - -286.58
12/31/24 - -374.12
Current Ratio
06/30/25 - -
03/31/25 - 3.62
12/31/24 - 2.55
Quick Ratio
06/30/25 - -
03/31/25 - 3.62
12/31/24 - 2.55
Operating Margin
06/30/25 - -
03/31/25 - -438.20
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -438.20
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -438.20
12/31/24 - -631.91
Book Value
06/30/25 - -
03/31/25 - 0.57
12/31/24 - 0.48
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©